SAB Biotherapeutics (SABS) Interest Expenses (2021 - 2026)
SAB Biotherapeutics (SABS) reported Interest Expenses of $62745.0 for Q1 2026, down 9.8% on a YoY basis from $69565.0 in Q1 2025, and down 1.13% quarter-over-quarter from $63462.0 in Q4 2025.
SAB Biotherapeutics (SABS) Interest Expenses (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Interest Expenses for 6 years, with the latest figure at $62745.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses fell 9.8% year-over-year to $62745.0; the trailing twelve-month figure through Mar 2026 stood at $233844.0 (down 24.95% YoY), and the FY2025 full-year result was $240664.0, down 24.41% from the prior year.
- Interest Expenses for Q1 2026 stood at $62745.0, down from $63462.0 in the prior quarter.
- The five-year high for Interest Expenses was $93119.0 in Q2 2024, with the low at $43292.0 in Q3 2025.
- Historically, Interest Expenses has averaged $72863.5 across 5 years, with a median of $71237.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 32.33% — and 2025, when it tumbled 44.52%.
- SAB Biotherapeutics' Interest Expenses stood at $87699.0 in 2022, then retreated by 11.2% to $77879.0 in 2023, then declined by 8.99% to $70876.0 in 2024, then fell by 10.46% to $63462.0 in 2025, then decreased by 1.13% to $62745.0 in 2026.
- The last three Interest Expenses figures came in at $62745.0 (Q1 2026), $63462.0 (Q4 2025), and $43292.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 62,745.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,745.00 |
| Mar 31, 2026 | 62,745.00 |
| Dec 31, 2025 | 63,462.00 |
| Dec 31, 2025 | 63,462.00 |
| Sep 30, 2025 | 43,292.00 |
| Sep 30, 2025 | 43,292.00 |
| Jun 30, 2025 | 64,345.00 |
| Jun 30, 2025 | 64,345.00 |
| Mar 31, 2025 | 69,565.00 |
| Mar 31, 2025 | 69,565.00 |
| Dec 31, 2024 | 70,876.00 |
| Dec 31, 2024 | 70,876.00 |
| Sep 30, 2024 | 78,036.00 |
| Sep 30, 2024 | 78,036.00 |
| Jun 30, 2024 | 93,119.00 |
| Jun 30, 2024 | 93,119.00 |
| Mar 31, 2024 | 76,371.00 |
| Mar 31, 2024 | 76,371.00 |
| Dec 31, 2023 | 77,879.00 |
| Dec 31, 2023 | 77,879.00 |